scholarly journals Aryl hydrocarbon receptor‐dependence of dioxin effects on constitutive mouse hepatic cytochromes P450 and growth hormone signaling components

2013 ◽  
Vol 27 (S1) ◽  
Author(s):  
David S Riddick ◽  
Chunja Lee
2006 ◽  
Vol 34 (9) ◽  
pp. 1530-1538 ◽  
Author(s):  
Chunja Lee ◽  
Janine R. Hutson ◽  
Vivien Kok-Fung Tzau ◽  
David S. Riddick

2012 ◽  
Vol 90 (10) ◽  
pp. 1354-1363 ◽  
Author(s):  
Chunja Lee ◽  
David S. Riddick

The aryl hydrocarbon receptor (AHR) has physiological roles in the absence of exposure to exogenous ligands, and mediates adaptive and toxic responses to the environmental pollutant 2,3,7,8-tetracholorodibenzo-p-dioxin (TCDD). A readily metabolized AHR agonist, 3-methylcholanthrene, disrupts the expression of mouse hepatic growth hormone (GH) signaling components and suppresses cytochrome P450 2D9 (Cyp2d9), a male-specific gene controlled by pulsatile GH via signal transducer and activator of transcription 5b (STAT5b). Using TCDD as an essentially nonmetabolized AHR agonist, and Ahr −/− mice as the preferred model to determine the AHR-dependence of biological responses, we now show that 2 mouse hepatic STAT5b target genes, Cyp2d9, and major urinary protein 2 (Mup2), are suppressed by TCDD in an AHR-dependent manner. TCDD also decreased hepatic mRNA levels for GH receptor, Janus kinase 2, and STAT5a/b with AHR-dependence. Without inducing selected hepatic inflammatory markers, TCDD caused AHR-dependent induction of Cyp1a1 and NADPH-cytochrome P450 oxidoreductase (Por) and suppression of Cyp3a11. In vehicle-treated mice, basal mRNA levels for CYP2D9, CYP3A11, POR, serum amyloid protein P, and MUP2 were influenced by Ahr genetic status. We conclude that AHR activation per se leads to dysregulation of hepatic GH signaling components and suppression of some, but not all, STAT5b target genes.


PLoS ONE ◽  
2016 ◽  
Vol 11 (10) ◽  
pp. e0164131 ◽  
Author(s):  
Takashi Fukuda ◽  
Tomoko Tanaka ◽  
Yuriko Hamaguchi ◽  
Takako Kawanami ◽  
Takashi Nomiyama ◽  
...  

2007 ◽  
Vol 14 (3) ◽  
pp. 901-906 ◽  
Author(s):  
A Raitila ◽  
M Georgitsi ◽  
A Karhu ◽  
K Tuppurainen ◽  
M J Mäkinen ◽  
...  

Germline mutations in the aryl hydrocarbon receptor interacting protein (AIP) gene were recently observed in patients with pituitary adenoma predisposition (PAP). Though AIP mutation-positive individuals with prolactin-, mixed growth hormone/prolactin-, and ACTH-producing pituitary adenomas as well as non-secreting pituitary adenomas have been reported, most mutation-positive patients have had growth hormone-producing adenomas diagnosed at relatively young age. Pituitary adenomas are also component tumors of some familial endocrine neoplasia syndromes such as multiple endocrine neoplasia type 1 (MEN1) and Carney complex (CNC). Genes underlying MEN1 and CNC are rarely mutated in sporadic pituitary adenomas, but more often in other lesions contributing to these two syndromes. Thus far, the occurrence of somatic AIP mutations has not been studied in endocrine tumors other than pituitary adenomas. Here, we have analyzed 32 pituitary adenomas and 79 other tumors of the endocrine system for somatic AIP mutations by direct sequencing. No somatic mutations were identified. However, two out of nine patients with prolactin-producing adenoma were shown to harbor a Finnish founder mutation (Q14X) with a complete loss of the wild-type allele in the tumors. These results are in agreement with previous studies in that prolactin-producing adenomas are component tumors in PAP. The data also support the previous finding that somatic AIP mutations are not common in pituitary adenomas and suggest that such mutations are rare in other endocrine tumors as well.


Pituitary ◽  
2020 ◽  
Author(s):  
David M. Carty ◽  
Rachael Harte ◽  
Russell S. Drummond ◽  
Rebecca Ward ◽  
Kesson Magid ◽  
...  

Abstract Pathogenic variants in the aryl hydrocarbon receptor-interacting protein (AIP) gene are increasingly recognised as a cause of familial isolated pituitary adenoma. AIP-associated tumours are most commonly growth hormone (GH) producing. In our cohort of 175 AIP mutation positive patients representing 93 kindreds, 139 (79%) have GH excess, 19 have prolactinoma (17 familial and 2 sporadic cases) and out of the 17 clinically non-functioning tumours 4 were subsequently operated and found to be GH or GH & prolactin immunopositive adenoma. Here we report a family with an AIP variant, in which multiple family members are affected by prolactinoma, but none with GH excess. To our knowledge this is the first reported family with an AIP pathogenic variant to be affected solely by prolactinoma. These data suggest that prolactinoma families represent a small subset of AIP mutation positive kindreds, and similar to young-onset sporadic prolactinomas, AIP screening would be indicated.


2017 ◽  
Author(s):  
Morten Hogild Pedersen ◽  
Ann Mosegaard Bak ◽  
Steen Bonlokke Pedersen ◽  
Niels Jessen ◽  
Niels Moller ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document